Paper324403
Bullous pemphigoid responding to sulfapyridine and the sulfones.
Person JR and 1 other. Arch Dermatol, 1977. Cited by 107 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Bullous pemphigoid responding to sulfapyridine and the sulfones. Papers, record 324403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/324403
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Skin Diseases, Vesiculobullous | Major topic |
| Sulfanilamides | Major topic |
| Sulfapyridine | Major topic |
| Sulfones | Major topic |
| Aged | |
| Autoantibodies | |
| Basement Membrane | |
| Candida albicans | |
| Complement C3 | |
| Diabetes Complications | |
| Esophagus | |
| Female | |
| Humans | |
| Immunoglobulin G | |
| Immunoglobulin M | |
| Liver Cirrhosis | |
| Male | |
| Middle Aged | |
| Streptococcus |
Source PubMed
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 107 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39,202,604 | Dapsone as a Current Option for the Treatment of Autoimmune Bullous Diseases with Autoimmunity to Non-Enzymes: A Retrospective Study from a Single Central European Referral Center. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39202604 | PubMed |
| 34,540,212 | A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions. | Ann Med Surg (Lond) | 2021 | https://conductscience.org/library/papers/34540212 | PubMed |
| 27,688,434 | Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology. | Indian J Dermatol | 2016 | https://conductscience.org/library/papers/27688434 | PubMed |
| 20,030,429 | Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management. | Drugs Aging | 2010 | https://conductscience.org/library/papers/20030429 | PubMed |
| 18,360,613 | Therapy of autoimmune bullous diseases. | Ther Clin Risk Manag | 2007 | https://conductscience.org/library/papers/18360613 | PubMed |
| 15,892,587 | Bullous pemphigoid: from bench to bedside. | Drugs | 2005 | https://conductscience.org/library/papers/15892587 | PubMed |
| 12,831,291 | Autoimmune bullous dermatoses in the elderly: diagnosis and management. | Drugs Aging | 2003 | https://conductscience.org/library/papers/12831291 | PubMed |
| 11,359,455 | The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. | Clin Exp Immunol | 2001 | https://conductscience.org/library/papers/11359455 | PubMed |
| 8,759,268 | Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid. | Br J Ophthalmol | 1996 | https://conductscience.org/library/papers/8759268 | PubMed |
| 3,296,406 | Cicatricial pemphigoid. | Trans Am Ophthalmol Soc | 1986 | https://conductscience.org/library/papers/3296406 | PubMed |
| 1,622,942 | Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. | Br J Ophthalmol | 1992 | https://conductscience.org/library/papers/1622942 | PubMed |
| 1,389,948 | The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients. | Br J Clin Pharmacol | 1992 | https://conductscience.org/library/papers/1389948 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/324403
GET https://conductscience.org/api/papers/v1/324403/authors